Athersys, Inc. (ATHX)
| Market Cap | 1.23M |
| Revenue (ttm) | 81,000 |
| Net Income (ttm) | -37.39M |
| Shares Out | 61.72M |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | 0.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,586,538 |
| Open | 0.0190 |
| Previous Close | 0.0211 |
| Day's Range | 0.0170 - 0.0230 |
| 52-Week Range | 0.0150 - 1.9900 |
| Beta | -0.78 |
| Analysts | Strong Buy |
| Price Target | 5.50 (+27,400.0%) |
| Earnings Date | Nov 9, 2023 |
About ATHX
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrom... [Read more]
Financial Performance
In 2022, Athersys's revenue was $5.33 million, a decrease of -3.43% compared to the previous year's $5.51 million. Losses were -$68.06 million, -21.73% less than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ATHX stock is "Strong Buy" and the 12-month stock price forecast is $5.5.
News
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results fo...
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indica...
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the inde...
Athersys Licenses its Animal Health Assets to Ardent Animal Health
CLEVELAND & LEXINGTON, Ky.--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Mu...
Athersys Director Jane Wasman Appointed Board Chair
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Direct...
Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samu...
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalent...
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results...
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema...
Athersys to Host Business Update Conference Call on August 9th
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will...
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys' MultiStem® Following Hemorrhagic Trauma
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollmen...
Athersys Restructures Debt with Supplier
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructure...
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15...
Athersys to Participate in Three Upcoming Conferences
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its partici...
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their parti...
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their parti...
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company's common stock (or...
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company's c...
Athersys to Host Business Update Conference Call on April 20th
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will...
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.
Athersys Announces Successful Type B Meeting with the FDA
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced planned amend...
Athersys Expands IP Protection with First New Patent for SIFU® Technology
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that th...
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that th...
Athersys to Host Business Update Conference Call on February 14th
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it wi...
Athersys to Participate in International Stroke Conference and BioProcess International
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its p...